| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 66 | 14.6x | 17.8x | Top tier | |
Growth | 15 | -0.6% | 7.1% | Bottom tier | |
Quality | 90 | 37.2% | 4.5% | Top tier | |
Safety | 60 | 2.1x | 2.6x | Around median | |
Capital Return | 49 | 6.15% | 2.12% | Around median | |
Momentum | 62 | -0.3% | 2.9% | Around median | |
Sentiment | 91 | 8 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Altria Group operates through a U.S. portfolio of nicotine products for adults, combining traditional cigarettes managed by Philip Morris USA, oral tobacco products and nicotine pouches developed by Helix, along with a financial investment in ABI. Profit generation depends heavily on Marlboro's strength in the premium segment and on pricing and product-mix management between Marlboro and Basic, while on! and on! PLUS represent the focus of expansion in smoke-free products.
In Q2 fiscal 2026, Altria reported revenue of $6.1 billion, gross profit of $3.8 billion, net income of $2.3 billion, and GAAP earnings per share of $1.37; this resulted in a calculated gross margin of approximately 62.3%. Adjusted diluted earnings per share increased 2.8% to $1.48, while reaching approximately $2.80 in the first half of fiscal 2026, representing growth of 4.9%.
The smokeable products segment remained the main financial driver, as its adjusted operating income increased 2.4% to $3.0 billion in Q2 fiscal 2026, with its margin expanding to 64.8%. By contrast, adjusted operating income for the oral tobacco products segment declined 8%, despite its margin remaining at 66.7%, due to a difficult comparison with the prior year and promotional investments in the launch of on! PLUS. Altria's equity-method earnings from ABI also totaled $158 million, up 21.5% from the comparable period.
The average analyst price target is $71.33, with a “Buy” consensus and a wide range of $58 to $79; the average is approximately 7.4% below the 52-week range high of $77.06, while the highest target exceeds that high. No price-to-earnings multiple is available in the provided data, so the valuation assessment is based on the 52-week range of $54.70–$77.06 and on the ability of adjusted earnings-per-share growth and shareholder returns to offset cigarette declines and legal and regulatory risks.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
The company reported revenue of $6.1 billion, net income of $2.3 billion, and GAAP earnings per share of $1.37. Gross profit totaled $3.8 billion, equivalent to a calculated margin of approximately 62.3%. Adjusted diluted earnings per share increased 2.8% to $1.48, primarily supported by a 2.4% increase in adjusted operating income for smokeable products to $3.0 billion.
on! PLUS showed positive share indicators, as on!'s retail share reached 8.6% in Q2 fiscal 2026, up 0.8 percentage points sequentially. The product also expanded to approximately 120 thousand stores, and on! shipments increased 5.1% during the first half. However, it has not yet fully offset the decline because on! shipments fell 4.2% in the same quarter and adjusted operating income for the oral tobacco products segment declined 8%.
In Q2 fiscal 2026, Helix resumed shipments of on! PLUS in the 12-milligram strength and three flavors in Florida, North Carolina, and Texas. Management scheduled a nationwide expansion of this strength for Q3 fiscal 2026. It also plans to launch Blueberry Mint and Mango Pineapple in 6-, 9-, and 12-milligram strengths beginning in Q4 fiscal 2026, leveraging NICOSILK soft-pouch technology.
Automated analysis for informational purposes only — not investment advice.
Adjusted domestic cigarette volumes declined 4.5% in Q2 fiscal 2026, compared with an estimated industry decline of 5%. Marlboro maintained 59.6% of the premium segment, but its total share declined 1.5 percentage points as the discount segment expanded by 2.6 percentage points. Philip Morris USA responded by supporting Basic in approximately 35 thousand stores and launching Marlboro Cowboy Cut for more value-sensitive consumers, while achieving net pricing of 4.5% for the smokeable products segment.
The company expects adjusted diluted earnings per share of between $5.61 and $5.72 in fiscal 2026. This represents growth of between 3.5% and 5.5% compared with earnings of $5.42 in fiscal 2025. Management raised the lower end of the range after adjusted diluted earnings per share grew 4.9% to $2.80 in the first half, but it noted continued pressure from inflation and fuel prices and the need to fund on! PLUS expansion.
Management believes the updated FDA priorities provide greater clarity, but they do not eliminate the need to obtain formal product authorizations. The company submitted a supplemental PMTA for a modified version of NJOY ACE after disputes involving four patents kept the product off the market, and it did not specify a date for its return. In Q2 fiscal 2026, illicit flavored vaping products remained widespread despite federal seizures exceeding $250 million and additional enforcement actions at the state and commercial-platform levels.
